These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24623949)

  • 1. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.
    Naredi N; Talwar P; Sandeep K
    Med J Armed Forces India; 2014 Jan; 70(1):58-63. PubMed ID: 24623949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    Tang H; Mourad S; Zhai SD; Hart RJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
    Gaafar S; El-Gezary D; El Maghraby HA
    Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.
    Torabizadeh A; Vahidroodsari F; Ghorbanpour Z
    Iran J Reprod Med; 2013 Oct; 11(10):837-42. PubMed ID: 24639705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
    Garcia-Velasco JA
    Reprod Biomed Online; 2009; 18 Suppl 2():71-5. PubMed ID: 19406035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.
    Kılıç N; Özdemir Ö; Başar HC; Demircan F; Ekmez F; Yücel O
    Avicenna J Med; 2015; 5(4):123-7. PubMed ID: 26629467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.
    Alper MM; Smith LP; Sills ES
    J Exp Clin Assist Reprod; 2009 Jun; 6():3. PubMed ID: 20485578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
    D'Angelo A; Amso N
    Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
    Lin YH; Huang MZ; Hwang JL; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Seow KM
    J Assist Reprod Genet; 2013 Jun; 30(6):753-9. PubMed ID: 23606010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.
    Busso CE; Garcia-Velasco J; Gomez R; Alvarez C; Simón C; Pellicer A
    Reprod Biomed Online; 2009 Jul; 19(1):43-51. PubMed ID: 19573289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.
    Fiedler K; Ezcurra D
    Reprod Biol Endocrinol; 2012 Apr; 10():32. PubMed ID: 22531097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso NN; Hassan R
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.